Quick Answer
PDS Biotechnology Corp reported R&D Expense of $19.03 million for fiscal year 2025.
PDS Biotechnology Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $19.03M | -15.7% |
| 2024 | $22.57M | -18.7% |
| 2023 | $27.76M | -5.7% |
| 2022 | $29.43M | +161.5% |
| 2021 | $11.25M | +42.0% |
| 2020 | $7.92M | +29.9% |
| 2019 | $6.10M | +634.2% |
| 2018 | $830.7K | -97.6% |
| 2017 | $34.31M | +38.2% |
| 2016 | $24.83M | +39.2% |
| 2015 | $17.84M | +110.5% |
| 2014 | $8.47M | +89.0% |
| 2013 | $4.48M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.58M | -32.7% | +8.6% |
| June 30, 2025 | $4.21M | -7.0% | -27.7% |
| March 31, 2025 | $5.83M | -13.0% | -14.3% |
| September 30, 2024 | $6.80M | +5.5% | +50.3% |
| June 30, 2024 | $4.53M | -43.4% | -32.5% |
| March 31, 2024 | $6.70M | +14.7% | +4.0% |
| September 30, 2023 | $6.45M | +48.1% | -19.4% |
| June 30, 2023 | $8.00M | +112.8% | +37.0% |
- PDS Biotechnology Corp showed a decrease of -15.7% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, PDS Biotechnology Corp’s r&d expense has grown by 324.3% (from $4.48 million to $19.03 million).
- The most recent figure is from PDS Biotechnology Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: